Journal: Cancers

Article Title: In Vitro Diffuse Large B-Cell Lymphoma Cell Line Models as Tools to Investigate Novel Immunotherapeutic Strategies

doi: 10.3390/cancers15010235

Figure Lengend Snippet: Overview of immunotherapeutic strategies and cell lines used in evaluation of their efficacy.

Article Snippet: Tafasitamab (anti-CD19 mAb) , B-ALL cell lines: SEM, Jurkat, CEM, MOLT-16, Nalm-6 cells , [ ] .

Techniques: Bioprocessing

Journal: Cancer Immunology, Immunotherapy

Article Title: Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer

doi: 10.1007/s00262-019-02344-6

Figure Lengend Snippet: Workflow for CTC capture and PD-L1 analysis

Article Snippet: The PD-L1 positive control cell line and the PD-L1 negative control cell line were obtained from InCellDx, Inc. (IncellDx, Menlo Park, CA, USA).

Techniques:

Journal: Cancer Immunology, Immunotherapy

Article Title: Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer

doi: 10.1007/s00262-019-02344-6

Figure Lengend Snippet: Examples of PD-L1 IHC staining of FFPE sections from NSCLC patients (× 100): a PD-L1(−) negative; b positive control (× 200), c PD-L1(+) positive, < 50% immunoreactive, d PD-L1(+) positive, > 50% immunoreactive

Article Snippet: The PD-L1 positive control cell line and the PD-L1 negative control cell line were obtained from InCellDx, Inc. (IncellDx, Menlo Park, CA, USA).

Techniques: Immunohistochemistry, Positive Control

Journal: Cancer Immunology, Immunotherapy

Article Title: Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer

doi: 10.1007/s00262-019-02344-6

Figure Lengend Snippet: PD-L1 expression levels in ten cancer cell lines and in PD-L1 positive and negative control cells from the BioINK staining kit

Article Snippet: The PD-L1 positive control cell line and the PD-L1 negative control cell line were obtained from InCellDx, Inc. (IncellDx, Menlo Park, CA, USA).

Techniques: Expressing, Negative Control, Staining

Journal: Cancer Immunology, Immunotherapy

Article Title: Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer

doi: 10.1007/s00262-019-02344-6

Figure Lengend Snippet: Example images of PD-L1 positive and negative staining patterns

Article Snippet: The PD-L1 positive control cell line and the PD-L1 negative control cell line were obtained from InCellDx, Inc. (IncellDx, Menlo Park, CA, USA).

Techniques: Negative Staining

Journal: Cancer Immunology, Immunotherapy

Article Title: Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer

doi: 10.1007/s00262-019-02344-6

Figure Lengend Snippet: CTC detection rate and PD-L1% in treatment-naïve NSCLC patients

Article Snippet: The PD-L1 positive control cell line and the PD-L1 negative control cell line were obtained from InCellDx, Inc. (IncellDx, Menlo Park, CA, USA).

Techniques:

Journal: Cancer Immunology, Immunotherapy

Article Title: Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer

doi: 10.1007/s00262-019-02344-6

Figure Lengend Snippet: 2 × 2 Confusion matrix and performance measures

Article Snippet: The PD-L1 positive control cell line and the PD-L1 negative control cell line were obtained from InCellDx, Inc. (IncellDx, Menlo Park, CA, USA).

Techniques: